Allakos Inc., a clinical stage biopharmaceutical company located in San Carlos, California, is making strides in the development of therapeutics that target immunomodulatory receptors on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody, lirentelimab (AK002), is currently in Phase III trials for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis, as well as in Phase II/III trials for eosinophilic esophagitis and a Phase II clinical trial for atopic dermatitis and chronic spontaneous urticaria. Allakos Inc. is not stopping there and is also working on developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis, while simultaneously moving forward with AK006 to treat allergic and inflammatory diseases. Furthermore, the company is conducting preclinical studies for AK007, a therapeutic solution that polarizes tumor-associated myeloid cells and promotes anti-tumor immunity. Established in 2012, Allakos Inc. is bringing cutting-edge advancements in biopharmaceuticals to the forefront with its innovative approaches to treating various diseases.